Clinical Trial Update: Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) [Phase 3]

View source ↗

Summary

Phase 3 trial of roflumilast (ARQ-154) 0.3% foam for seborrheic dermatitis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seborrheic Dermatitis

Drugs mentioned

• Roflumilast (ARQ-154) Foam 0.3% (roflumilast)

Snippet

Sponsor: Arcutis Biotherapeutics, Inc. | Conditions: Seborrheic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2024-03-12